Paget's disease of bone treated with a five day course of oral tiludronate.
Chloro-4-phenyl thiomethylene bisphosphonate (tiludronate) is a new drug which can be used as an inhibitor of bone resorption. As it remains in bone for a long time, and as mineralisation defects have only been seen at doses much higher than those required to decrease osteoclastic activity, it could...
Guardat en:
| Publicat a: | Ann Rheum Dis |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMJ Publishing Group
1993
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC1004956/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/8427515/ https://ncbi.nlm.nih.govhttps://doi.org/10.1136/ard.52.1.54 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|